ഇൻഫർമേഷൻ
കൂടുതൽ തരങ്ങൾ
ബ്ലോഗുകൾ
വാർത്തകൾ
മീഡിയ
Read Now
Hi everyone, join Dr. Aju Mathew as he delves into the recent Union Budget 2024 announcements. This year, the finance minister declared a customs duty waiver on three significant cancer drugs: Enhertu (ado-trastuzumab deruxtecan, Osimertinib (Tagrisso), and Imfinzi (Durvalumab). While this news brings relief to some cancer patients, many others still await broader reforms. Dr. Mathew discusses the implications, the need for more transparent decision-making, and calls for further measures like compulsory licensing and affordable insurance for all cancer patients.